医学
间皮瘤
恶性胸腔积液
胸腔积液
胸膜疾病
放射科
病理
呼吸道疾病
内科学
肺
作者
Sanjeevan Muruganandan,Victor Duong
出处
期刊:Chest
[Elsevier]
日期:2021-11-01
卷期号:160 (5): 1602-1603
被引量:1
标识
DOI:10.1016/j.chest.2021.06.074
摘要
Malignant pleural mesothelioma (MPM) is a disease that portends a poor prognosis with a median survival that ranges from 8 to 14 months after diagnosis (5-year survival rate: 5.5%).1 Malignant pleural effusion (MPE) is the most common first presentation of MPM; >95% of individuals with MPM will experience a pleural effusion during their lifetime.2 At present, there is no cure for MPM; numerous therapeutic approaches have been attempted with modest results.1 Like other forms of malignant pleural disease, management of MPE related to MPM is directed towards palliation of symptoms.
科研通智能强力驱动
Strongly Powered by AbleSci AI